<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460108</url>
  </required_header>
  <id_info>
    <org_study_id>EK_11_027_0311</org_study_id>
    <nct_id>NCT01460108</nct_id>
  </id_info>
  <brief_title>AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation</brief_title>
  <acronym>CV+</acronym>
  <official_title>Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and efficacy of the AeriSeal System
      in patients with advanced upper lobe predominant emphysema and significant collateral
      ventilation as determined by the Chartis System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator initiated, open-label, uncontrolled study to prospectively
      characterize the safety and efficacy of the AeriSeal System in patients with advanced upper
      lobe predominant emphysema found to have significant collateral ventilation using the Chartis
      System.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Forced Expiratory Volume in one second (FEV1)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from baseline in FEV1 measurement after 12 weeks following completion of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in one second (FEV1).</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in FEV1 at 24 Weeks following completion of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>12 Weeks and 24 Weeks</time_frame>
    <description>Change from baseline in FVC at 12 and 24 weeks following completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio of Residual Volume to Total Lung Capacity (RV/TLC)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in RV/TLC ratio at 24 weeks following completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distance walked in six minutes (6MWT)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in 6MWT distance at 24 weeks following completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medical Research Council Dyspnea (MRCD) score</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in MRCD score at 24 weeks following completion of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life assessment (St. George's Respiratory Questionnaire)(SGRQ)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in disease-specific health related quality of life assessment (SGRQ) at 24 weeks following completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Collateral Ventilation</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in collateral ventilation at 24 weeks following completion of therapy as measured by the Chartis System.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unanticipated Serious Adverse Device Effects (USADEs)</measure>
    <time_frame>24 Week</time_frame>
    <description>Record of any/all USADEs up to 24 weeks follwoing completion of therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pulmonary Emphysema</condition>
  <condition>COPD</condition>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>AeriSeal System Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candidates for the trial include patients with advanced non-bullous upper lobe predominant emphysema who have a DLco between 20 and 60% predicted and target sites in at least 1 upper lobe. Eligible and consented patients will undergo evaluation with the Chartis System, and only patients found to have significant collateral ventilation will be enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AeriSeal System</intervention_name>
    <description>20 mL</description>
    <arm_group_label>AeriSeal System Treatment</arm_group_label>
    <other_name>Emphasemateous Lung Sealant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent and to participate in the study

          -  Diagnosis of advanced emphysema (GOLD Stage III or Stage IV disease)

          -  Radiologic evidence of non-bullous upper lobe predominant heterogeneous emphysema with
             at least 2 target sites deemed appropriate for treatment evident by CT imaging

          -  DLco between 20 and 60% predicted

          -  Positive Collateral Ventilation as determined by the Chartis® System

          -  Clinically significant dyspnea (defined as a MRC dyspnea score of 2 or greater at
             Screening)

          -  Failure of standard medical therapy to provide adequate relief of symptoms (defined as
             regular use of standard medication for more than 1 month prior to Screening; standard
             medications include at least an inhaled beta agonist and inhaled anticholinergic
             unless medically contraindicated or prior medical failure)

          -  Significant airflow obstruction as demonstrated by Spirometry 15 minutes after
             administration of bronchodilator with:

          -  5% &lt; FEV1 &lt; 50% predicted using the ATS recommended calculation for expected value

          -  FEV1/FVC ratio &lt;70%

          -  Physiological evidence of hyperinflation with Lung volumes (plethysmographic) of:

          -  TLC &gt; 100% predicted using the ATS recommended calculation for expected value

          -  RV &gt; 135% predicted using the ATS recommended calculation for expected value

          -  Six-Minute Walk Test distance ≥ 150 m

          -  Abstinence from inhaled tobacco use for at least 16 weeks prior to the initial
             Screening visit until the end of the study

          -  Female patients are either post-menopausal or surgically sterile. Women with
             child-bearing potential will not be included in this study

        Exclusion Criteria:

          -  Alpha-1 antitrypsin serum level of &lt; 80 mg/dL (i.e. &lt; 11 micro mol/L) at Screening

          -  Body mass index &lt; 15 kg/m2 or &gt; 35 kg/m

          -  Clinically significant asthma, chronic bronchitis or bronchiectasis as determined by
             the Investigator, or a significant COPD exacerbation within the past 4 months

          -  Use of systemic steroids &gt; 20 mg/day or equivalent immunosuppressive agents, heparins,
             oral anticoagulants (e.g., warfarin, dicumarol; note: antiplatelet drugs including
             aspirin and clopidogrel are permitted) or investigational medications within 4 weeks
             of Screening

          -  Allergy or sensitivity to medications required to safely perform AeriSeal System
             treatment under general anesthesia or conscious sedation

          -  Participation in an investigational study of a drug, biologic, or device not currently
             approved for marketing within 30 days prior to the Screening visit

          -  Prior lung volume reduction surgery, prior lobectomy or pneumonectomy, prior lung
             transplantation, prior airway stent placement, prior pleurodesis, or prior
             endobronchial lung volume reduction therapy of any type

          -  Significant co-morbidity that carries prohibitive risks (e.g., HIV/AIDS, cancer) or is
             associated with less than 2-year expected survival

          -  Blood gases and oxygen saturation:

               -  SpO2 ≤ 90% on &gt; 4 L/min supplemental O2, at rest

               -  PaCO2 ≥ 55mmHg

               -  DLCO &lt; 20% or &gt; 60% predicted for patients with heterogeneous emphysema

          -  Chest CT scan: Presence of any of the following radiologic abnormalities:

               -  Pulmonary nodule on CT scan greater than 1.0 cm in diameter (Does not apply if
                  present for 2 years or more without increase in size or if proven benign by
                  biopsy/PET)

               -  Giant Bullous Disease

               -  Radiologic picture consistent with active pulmonary infection, e.g., unexplained
                  parenchymal infiltrate

               -  Significant interstitial lung disease (based upon investigator judgment)

               -  Significant pleural disease (based upon investigator judgment)

               -  Any condition that the Investigator believes would interfere with the intent of
                  the study or would make participation not in the best interest of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arschang Valipour, MD, FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Boltzmann-Institut für COPD und Pneumologische Epidemiologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arschang Valipour, MD, FCCP</last_name>
    <phone>43-1-91060-41008</phone>
    <email>arschang.valipour@wienkav.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Otto-Wagner-Spital</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arschang Valipour, MD, FCCP</last_name>
      <phone>43-1-91060-41008</phone>
      <email>arschang.valipour@wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Arschang Valipour, MD, FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2011</study_first_posted>
  <last_update_submitted>October 26, 2011</last_update_submitted>
  <last_update_submitted_qc>October 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology</investigator_affiliation>
    <investigator_full_name>Arschang Valipour</investigator_full_name>
    <investigator_title>Ass. Prof. Department of Respiratory and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>PLVR</keyword>
  <keyword>AeriSeal</keyword>
  <keyword>Treatment</keyword>
  <keyword>Device</keyword>
  <keyword>Breathing</keyword>
  <keyword>COPD</keyword>
  <keyword>emphysema</keyword>
  <keyword>polymeric lung volume reduction</keyword>
  <keyword>heterogeneous</keyword>
  <keyword>homogeneous</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

